Kanagawa-ken, Japan

Kimihisa Ichikawa

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 5.0

ph-index = 7

Forward Citations = 89(Granted Patents)


Location History:

  • Yokohama, JP (2004 - 2010)
  • Tokyo, JP (2010 - 2012)
  • Edogawa-ku, JP (2013)
  • Kanagawa-Ken, JP (2007 - 2017)

Company Filing History:


Years Active: 2004-2017

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Kimihisa Ichikawa: Innovator in Antibody Research

Introduction

Kimihisa Ichikawa is a prominent inventor based in Kanagawa-ken, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target specific receptors involved in cell growth and apoptosis. With a total of 13 patents to his name, Ichikawa's work has the potential to impact treatments for various diseases.

Latest Patents

Ichikawa's latest patents include innovative antibodies selective for the tumor necrosis factor-related apoptosis-inducing ligand receptor, known as DR5. These antibodies interact with human DR5 to produce both agonistic and antagonistic effects downstream of the receptor. This interaction can lead to the inhibition of cell proliferation and apoptosis. The patents detail the nucleic acid and amino acid sequences of these anti-DR5 antibodies, as well as the vectors and cells that express these sequences. The methods and uses for these antibodies are particularly relevant for treating apoptosis-related diseases and addressing dysregulated cell growth.

Career Highlights

Throughout his career, Ichikawa has worked with notable organizations, including the UAB Research Foundation and Sankyo Company, Limited. His research has focused on the therapeutic applications of antibodies, contributing to advancements in medical science.

Collaborations

Ichikawa has collaborated with esteemed colleagues such as Tong Zhou and Robert P Kimberly. These partnerships have further enriched his research and development efforts in the field of antibody technology.

Conclusion

Kimihisa Ichikawa's innovative work in antibody research exemplifies the potential of biotechnology to address critical health challenges. His contributions continue to pave the way for new therapeutic strategies in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…